These figures show that TP53INP1 exhibits lower expression in endometrial cancer samples compared to normal endometrial tissues, and that its correlation with hsa-miR-182 is significantly negative (R = −0.72) in stage IV of the disease. Here, TP53INP1 is linked to endometrial cancer.